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Aims. To assess the incremental prognostic value of SYNTAX score II (SxSII) as compared to anatomical SYNTAX Score (SxS) and
GRACE risk score in patients with acute coronary syndromes who underwent percutaneous coronary intervention. Methods and
results. SxSII and SxS were determined in 734 ACS patients. Patients were enrolled in the prospective Special Program University
Medicine ACS and the COMFORTABLE AMI cohorts and later on stratiﬁed according to tertiles of SxSII (SxSIILow ≤21.5 (n � 245),
SxSIIMid 21.5–30.6 (n � 245), and SxSIIHigh ≥30.6 (n � 244). e primary endpoint of adjudicated all-cause mortality and secondary
endpoints of MACE (cardiac death, repeat revascularization, and myocardial infarction) and MACCE (all-cause mortality, cere-
brovascular events, MI, and repeat revascularization) were determined at 1-year follow-up. SxSII provided incremental predictive
information for risk stratiﬁcationwhen compared to SxS andGRACE risk score (AUC0.804, 95%CI 0.77–0.84,p< 0.001 versus 0.67,
95% CI 0.63–0.72, p � 0.007 versus 0.69, 95% CI 0.6–0.8, p � 0.002), respectively. In a multivariable Cox regression analysis, we
found that unlike SxS (adjusted HR 1.013, 95% CI (0.96–1.07), p � 0.654), SxSII was signiﬁcantly associated with all-cause mortality
(HR� 1.095, 95% CI (1.06–1.11), p< 0.001). is was also true for the prediction of both secondary outcomes MACE (n � 60) and
MACCE (n � 70) with an adjusted HR� 1.055, 95% CI (1.03–1.08), p< 0.001, and HR� 1.065, 95% CI (1.04–1.09), p< 0.001.
Conclusion. In patients with ACS who underwent PCI, SxSII is an independent predictor of mortality during 1-year follow-up. SxSII
shows superiority in discriminating risk compared to conventional SxS and GRACE for all-cause mortality.
1. Introduction
e anatomical SYNTAX (Synergy between percutaneous
coronary intervention with taxus and cardiac surgery) score
(SxS) is an angiographic scoring system for assessing the
complexity of coronary artery disease (CAD) [1] advocated
for decision making in the latest ESC/EACTS guidelines on
myocardial revascularization [2]. Originally, the SxS was
introduced to predict clinical outcomes in stable patients with
3-vessel and/or left main disease undergoing percutaneous
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coronary intervention (PCI) or coronary artery bypass grafting
(CABG), respectively, based on data from the SYNTAX trial
[3, 4]. Later on, the SxS was applied to a variety of patient
populations with diverse clinical presentations including those
with acute coronary syndromes (ACS) undergoing primary
PCI [5, 6].
However, subanalyses of the SYNTAX trial and results
from diﬀerent studies have implied that the purely anatomy-
based risk stratiﬁcation of the SxS score made it prone to
misclassiﬁcation of patient’s true risk, particularly for all-
cause mortality and cardiac death in patients with stable
CAD or ACS treated by PCI [7, 8]. e addition of clinical
variables was a promising step in improving risk stratiﬁ-
cation by reclassifying patients into more accurate risk
categories. erefore, in order to account for the variability
of clinical parameters aﬀecting long-term outcomes and
hence better classiﬁcation of patients’ risk, the SYNTAX
score II (SxSII) was developed by complementing SxS with 7
prognostic variables including age, creatinine clearance, left
ventricular ejection fraction (LVEF), presence of un-
protected left main coronary artery (ULMCA) disease, pe-
ripheral vascular disease (PVD), female gender, and chronic
obstructive pulmonary disease (COPD) [9]. So far, the SxSII
was validated in patients with left main and multivessel
disease showing more accurate patient stratiﬁcation than
SxS [10, 11, 12].
e aim of the present study was to assess the predictive
performance of SxSII in patients presenting with ACS un-
dergoing PCI and to compare it to the previously validated
SxS and the commonly used Global Registry of Acute
Coronary Events (GRACE) risk score [13].
2. Methods
2.1. Study Population. e prospective multicenter Special
Program University Medicine—Acute Coronary Syndromes
and Inﬂammation (SPUM-ACS, ClinicalTrials.gov number,
NCT01000701) enrolled consecutive patients who were re-
ferred for coronary angiography with a diagnosis of ACS to
one of the participating Swiss university hospitals (Zurich,
Bern, Lausanne, and Geneva) between December 2009 and
October 2012 [14, 15]. Inclusion criteria comprised patients
of both genders, aged ≥18 years, presenting within 5 days
(preferably within 72 hours) after pain onset with a main
diagnosis of STEMI, NSTEMI, or unstable angina. Enrolled
patients had symptoms compatible with angina pectoris
(chest pain and dyspnea) and fulﬁlled at least one of the
following criteria: (a) ECG changes, such as persistent ST-
segment elevation or depression, T-inversion or dynamic
ECG changes, or new left bundle branch block (LBBB); (b)
evidence of positive (predominantly conventional) troponin
by local laboratory reference values (with a rise and/or fall in
serial troponin levels); and (c) known coronary artery dis-
ease speciﬁed by its status after MI, coronary artery bypass
graft (CABG), or PCI or newly documented ≥50% stenosis
of an epicardial coronary artery during the initial cathe-
terization. Exclusion criteria for the SxSII study comprised
prior CABG, referral to either CABG or medical man-
agement after completion of the coronary angiogram,
severe physical disability, and inability to comprehend
study or less than 1 year of life expectancy for noncardiac
reasons. Within this consortium, a centralized electronic
database was implemented providing comprehensive in-
formation on all patients comprising both clinical and
coronary anatomy parameters. A telephone follow-up was
performed at 30 days and at 1 year, a clinical visit. Adverse
events occurring within 365 days after the index ACS event
were adjudicated by an independent adjudication com-
mittee consisting of 3 experienced cardiologists (Lukas
Kappenberger, MD, Lausanne; Tiziano Moccetti, MD
Lugano; and Mathias E. Pﬁsterer, MD, Basel). An addi-
tional 3-year follow-up to assess all-cause mortality was
ascertained by telephone for the SxSII study, and only
patients recruited in Bern and Zurich were analyzed in the
SxSII study. e study was approved by the local ethical
committees, and all patients gave written informed consent
in compliance with the Declaration of Helsinki.
e COMFORTABLE AMI trial included patients aged
18 years or older who had a history of chest pain of more
than a 10min duration and associated ST-segment eleva-
tion of >1mm in ≥2 contiguous leads, new left bundle
branch block, or true posterior MI, who underwent pri-
mary percutaneous coronary intervention (PCI) within
24 h of symptom onset. In addition, there was angiographic
presence of at least one acute infarct-related artery (IRA)
with one or multiple coronary artery lesions in a native
coronary artery with a diameter between 2.25 and 4.0mm,
which could be treated with one or multiple stents. Ex-
clusion criteria included the use of vitamin K antagonists,
mechanical complications of myocardial infarction, acute
myocardial infarction secondary to stent thrombosis (ST),
planned surgery within 6 months of PCI unless dual
antiplatelet therapy could be maintained throughout the
perisurgical period, and noncardiac comorbid conditions
with life expectancy <1 year. Further study details are
described in detail elsewhere [16].
Angiography was digitally recorded and analyzed in
a central core laboratory. e MI SxS score was assessed by
experienced analysts using the web-based program http:
//www.syntaxscore.com as previously described. Angio-
graphic documentation of patients included in the
COMFORTABLE AMI trial was scored as described
previously.
2.2.ClinicalOutcomes. All-cause mortality included cardiac,
vascular, and noncardiovascular causes of death. Cerebro-
vascular events comprised stroke (any, ischemic, hemor-
rhagic, and unclear etiology) or transient ischemic attack
(TIA); repeat revascularization included any repeat coronary
revascularization (target and nontarget vessel). Clinically
indicated repeat revascularization included any clinically
driven repeat coronary revascularization (target and non-
target vessel) [17]. Myocardial infarction was deﬁned based
on the universal deﬁnition including periprocedural MI in
patients with UA [18].
e primary endpoint of our study was adjudicated
all-cause mortality at 1-year follow-up. e secondary
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endpoints were adjudicated major adverse cardiovascular
events (MACE) deﬁned as the composite of cardiac death,
clinically indicated revascularization, or MI at 1 year and
adjudicated major adverse cardiovascular and cerebrovas-
cular events (MACCE) deﬁned as the composite of all-cause
mortality, cerebrovascular events, any repeat re-
vascularization, or myocardial infarction (MI) at 1-year,
respectively.
2.3. Anatomical SYNTAX Score, SYNTAX Score II, and
GRACE Risk Score Calculation. Experienced cardiologists
blinded to clinical outcomes assessed the SYNTAX score for
each angiogram. e interobserver and intraobserver var-
iabilities of the SxS scoring team were previously reported
as moderate (kappa statistic 0.56) and substantial (kappa
statistic 0.70, respectively). e intraclass correlation co-
eﬃcient for calculated SXS in SPUM cohort for absolute
agreement was 0.886 (p< 0.001), 95% CI (0.835, 0.919).
Before accessing any lesions, all those with ≥50% diameter
stenosis in vessels ≥1.5mm in diameter were scored using
the SxS algorithm [1]. e SxSII was then calculated using
the PCI SYNTAX score II (http://www.syntaxscore.com)
calculator based on the previously published nomogram
[9], with scores assigned for the presence and magnitude of
each predictor speciﬁc for PCI population [9, 11]. e
GRACE risk score to calculate long-term mortality com-
prised age, heart rate, systolic blood pressure, initial serum
creatinine, history of congestive heart failure, history of
myocardial infarction, elevated cardiac markers (conven-
tional troponins as per local laboratories), ST-segment
depression, and no in-hospital PCI [13]. e long-term
GRACE risk score was calculated using a program written
in STATA, and we used the standard scoring of GRACE as
mentioned in the reference publications. (http://www.
wikidoc.org/index.php/e_GRACE_risk_score). It was
retrospectively calculated for all patients included in our
study and was compared to SxSII and SxS as a continuous
variable by ROC curve analysis and multivariable Cox
regression model.
2.4. Statistical Analysis. Continuous variables are expressed
as mean± SD or medians with interquartile ranges (IQR)
and were compared using one-way ANOVA, Student’s t-
test, Kruskal–Wallis test, or Mann–Whitney test as appro-
priate. Categorical data are presented as frequency (per-
centages) and were compared using the Fisher exact or the
chi-square test. Cumulative incidences were calculated using
Kaplan–Meier curves.
For our analysis, we stratiﬁed patients according to
tertiles of SxSII [9] (≤21.5, 21.5–30.6, ≥30.6) and SXS (≤12,
12–22, ≥22). e score ranges are referred to as SxSIILow,
SxSIIMid, and SxSIIHigh and SxSLow, SxSMid, and SxSHigh,
respectively. We constructed multivariable Cox pro-
portional hazard models including variables that had a sig-
niﬁcant association with a p value of <0.05 in univariable
analysis. We further added SxS and SxSII separately into the
model due to their collinearity. Other variables showed no
multicollinearity that exceeding the acceptable threshold of
VIF ≥3 or tolerance ≤0.2. From the full model, we selected
variables to minimize Akaike’s information criterion by
backward stepwise methods. Calibration was then de-
termined by the Hosmer–Lemeshow goodness-of-ﬁt test.
To visualize the eﬀect of SxSII on clinical outcomes and
conﬁrm its linearity, we constructed an alternative model
using penalized splines. Analyses were performed with
SPSS version 21.0 software (SPSS Inc., Chicago, Ill).
ROC curves were constructed to assess the ability of the
SxSII, SxS, and GRACE risk score to predict events at 1-
year follow-up. Patients who were lost to follow-up at 1
year were excluded from the analysis. Areas under curves
were compared using the DeLong method [19] provided by
MedCalc for Windows, version 14.10.2 (MedCalc Software,
Acacialaan, Belgium). Category-free net reclassiﬁcation
improvement (NRI) and integrated discrimination im-
provement (IDI) were both calculated using the “survI-
DINRI,” R package (R-version 3.3.2), through comparing
proportional hazards models, whereas category-based NRI
was done using MATLAB version R2015b, all as described
by Pencina et al. [20]. A probability value of <0.05 was
considered signiﬁcant, and all tests were two-tailed.
3. Results
3.1. Baseline and Angiographic Characteristics for Tertiles of
SYNTAX Score II. SxS and SxSII could be calculated for all
734 patients with a complete one-year follow-up. e mean
anatomical SYNTAX score was 17.56 ± 9.3 with a median of
16 with an interquartile range (IQR) of 13. Patients were
categorized into SxS tertiles (SxSLow, n � 251, SxSMid,
n � 244, and SxSHigh, n � 239). e mean SYNTAX score II
was 27.7 ± 10.3 with a median of 25.4. e number of
patients stratiﬁed according to tertiles of SxSIILow, SxSIIMid,
and SxSIIHigh, was 245, 245, and 244, respectively. e
tertiles of SxSII and its individual components including
the anatomical SYNTAX score are listed in Table 1 as they
are compared to tertiles of the conventional SxS.
Compared with patients in the lower tertiles, patients in
SxSIIHigh had a higher rate of adverse cardiovascular his-
tory and risk factors and fasting glucose, along with he-
modynamic instability on admission. e baseline
characteristics and risk factors of patients according to
SxSII tertiles are listed in Table 2. Angiographic charac-
teristics showed signiﬁcant diﬀerences with a higher rate of
MVD with left anterior descending artery (LAD) in-
volvement (74.2%) in the SxSIIHigh tertile compared with
patients in the lower tertiles (Table 3).
3.2. Clinical Outcomes Stratiﬁed by Tertiles of Anatomical
SYNTAX and SYNTAX Score II. In order for better as-
sessment of the impact SxSII has on mortality, we expressed
this relationship in terms of penalized splines curves (hazard
ratio-based curves) obtained through a Cox proportional
hazard regression model (Supplementary Figure 1). As the
relationship was curve-linear, our choice of breaking the
score into tertiles was justiﬁed.
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Patients within the SxSIIHigh tertile had a signiﬁcantly
higher incidence of all-cause mortality, MACE, andMACCE
compared with patients in lower tertiles (Table 4). ere was
also a higher rate of clinically driven revascularization, in
SxSIIHigh (8.6% p � 0.002) with a trend for excess cere-
brovascular events, p � 0.134. One-year outcomes across the
tertiles of SxS are reported in Supplementary Table 1.
Furthermore, Kaplan–Meier curves were plotted to asses
all studied outcomes across tertiles of both SxS and SxSII as
shown in Figure 1. All-cause mortality (9.4% versus 1.2%
versus 0.8%), MACCE (17.6% versus 8.6% versus 2.4%),
and MACE (14.3% versus 8.2% versus 2%) occurred at
a signiﬁcantly higher rate among patients in SxSIIHigh
compared to SxSIIMid and SxSIILow, respectively (p (log
rank) <0.001). Conversely, the anatomical SYNTAX score
does not provide consistent risk stratiﬁcation, speciﬁcally
when addressing the primary endpoint of all-cause mor-
tality at 1 year.
Table 1: Baseline characteristics and risk factors.
Variables SxSIILow ≤21.5 SxSIIMid 21.5–30.6 SxSIIHigh ≥30.6 p value
N � 245 N � 245 N � 244
Age∗ 52.3± 7.4 60.5± 9.5 71.7± 10.2 N/A
Gender (male)∗ 239 (97.6) 205 (83.7) 146 (59.8) N/A
ACS 0.001
STEMI 167 (68.2) 181 (73.9) 189 (77.5)
NSTE-ACS 65 (26.5) 63 (25.7.4) 53 (21.7)
Unstable angina 13 (5.3) 1 (0.4) 2 (0.8)
Hypertension 100 (43.1) 122 (51.7) 155 (68) <0.001
History of dyslipidemia 143 (61.9) 140 (59.6) 138 (60.8) 0.878
Diabetes mellitus 28 (12.1) 41 (17.4) 39 (17.1) 0.207
History of smoking 207 (84.5) 188 (76.7) 142 (59.2) <0.001
History of CAD 72 (31.9) 57 (24.2) 38 (17.5) 0.002
Prior MI 11 (4.7) 20 (8.5) 25 (11) 0.049
Prior PCI 19 (8.2) 25 (10.5) 28 (12.3) 0.347
History of PVD∗ 0 (0) 1 (0.4) 23 (9.4) N/A
History of COPD∗ 3 (1.2) 6 (2.4) 15 (6.1) N/A
Killip score ≥2 21 (8.5) 31 (12.7) 46 (18.9) 0.003
Prehospital resuscitation 16 (6.5) 8 (3.3) 10 (4.1) 0.226
Vasopressors 5 (2) 4 (1.6) 15 (6.1) 0.007
IABP 3 (1.2) 9 (3.7) 33 (13.5) <0.001
BMI (kg/m2) 27.7± 3.9 27.5± 4.2 25.6± 3.6 <0.001
HsTnT (ug/l) 0.14 (0.04/0.51) 0.18 (0.04/0.67) 0.24 (0.08/0.73) 0.008
CK-MB (U/l) 24.3 (11/57) 28.5 (12/68) 34 (14/66) 0.104
NT-proBNP (ng/l) 137 (47/311) 256 (95/701) 586 (195/1960) <0.001
eGFR (ml/min/1.73m2)∗ 127.8± 30.8 106.9± 33.6 69.5± 29.4 N/A
Fasting glucose (mmol/l) 6.8± 2.2 7.4± 2.9 7.8± 3.4 0.001
LVEF (%)∗ 55.7± 7.4 50.7± 10.2 45.9± 12.4 N/A
Depicted are counts, n incidence (%) or mean± SD or median (25/75) percentile. ∗Variables are included in the score; p value reported as N/A. CAD,
coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; COPD, chronic obstructive
pulmonary disease; LVEF, left ventricular ejection fraction.
Table 2: Components of SYNTAX score II.
Variables SxSIILow ≤21.5 SxSIIMid 23–32 SxSIIHigh ≥30.6 p value
N � 245 N � 245 N � 244
Age 52.3± 7.4 60.5± 9.5 71.7± 10.2 <0.001
Gender (male) 239 (97.6) 205 (83.7) 146 (59.8) <0.001
PVD 0 (0) 1 (0.4) 23 (9.4) <0.001
COPD 3 (1.2) 6 (2.4) 15 (6.1) 0.004
eGFR (ml/min/1.73m2) 127.8± 30.8 106.9± 33.6 69.5± 29.4 <0.001
LVEF (%) 55.7± 7.4 50.7± 10.2 45.9± 12.4 <0.001
LM 2 (0.8) 2 (0.8) 10 (4.1) 0.009
Anatomical SYNTAX score (SxS) 12.6± 6.9 17.6± 7.8 22.4± 10.2 <0.001
Variables SxSLow ≤12 SxSMid 12-22 SxSHigh ≥22 p value
N � 251 N � 244 N � 239
Anatomical SYNTAX score (SxS) 7.9± 2.8 16.9± 2.91 28.5± 6.4 <0.001
PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; GFR, glomerular ﬁltration rate; LM,
left main disease.
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Table 3: Angiographic characteristics and medications.
Variables SxSIILow <23 SxSIIMid 23–32 SxSIIHigh ≥23 p value
N � 176 N � 164 N � 160
Vessel involvement
LM∗ 2 (0.8) 2 (0.8) 10 (4.1) N/A
LAD 121 (49.4) 157 (64.1) 181 (74.2) <0.001
LCx 72 (29.4) 83 (34) 84 (34.4) 0.419
RCA 125 (51) 126(51.6) 134 (54.9) 0.654
MVD# of vessels 86 (35.1) 106 (43.3) 130 (53.3) <0.001
2 vessels 72(29.4) 71(29) 83(34)
3 vessels 14(5.7) 35(14.3) 47(19.3)
ACC/AHA lesion classiﬁcation 0.413 0.413
Type A lesion 15 (9.6) 18 (11.7) 10 (7.0)
Type B1 lesion 73 (46.8) 56 (36.4) 60 (42.3)
Type B2 lesion 41 (26.3) 45 (29.2) 37 (26.1)
Type C lesion 27(17.3) 35 (22.7) 35 (24.6)
Restenotic lesion 7 (2.9) 6 (2.4) 5 (2.1) 0.876
Bifurcation lesion 20 (8.3) 28 (11.5) 27 (11.2) 0.441
=rombus Procedural details 132 (54.3) 120(49) 107(44.2) 0.083
Length of 1st stent 25.4± 5 20.2± 5 25.4± 5
Diameter of 1st stent 3.03± 0.68 2.9± 0.41 2.81± 0.22
Length of 2nd stent 19.85± 6.83 23.6± 6.12 18.2± 5.6
Diameter of 2nd stent 3.1± 0.28 3± 0.68 2.6± 0.13
Length of 3rd stent 15.9± 7.02 12.4± 2.8 16.2± 9
Diameter of 3rd stent 3.17± 0.31 2.95± 0.77 2.65± 0.48
TIMI ﬂow 0.207
TIMI 0 107 (44.4) 134 (54.9) 128 (53.1)
TIMI I 20 (8.3) 15 (6.1) 10 (4.1)
TIMI II 38 (15.8) 33 (13.5) 36 (14.9)
TIMI III 76 (31.5) 62 (25.4) 67 (27.8)
Medications on admission
ASA 213 (86.9) 205 (83.7) 159 (65.7) <0.001
Clopidogrel 6 (2.5) 7 (2.9) 14 (5.8) 0.125
Prasugrel/ticagrelor 1 (0.6) 0 (0) 0 (0) 1
Statin 34 (14) 48 (19.6) 63 (26.1) 0.004
Beta blocker 31(12.7) 43 (17.6) 68 (28.3) <0.001
Procedural antiplatelet Tx
Clopidogrel 119 (69.2) 120 (73.2) 117 (73.6) 0.451
Prasugrel 63 (35.8) 46 (28.0) 26 (16.4) <0.001
Depicted are counts, n incidence (%) or mean± SD.∗variables are included in the score; p value reported as N/A. LAD, left anterior descending artery; RCA,
right coronary artery; LCX, circumﬂex artery; TIMI, thrombolysis in myocardial infarction; AHA, American Heart Association.
Table 4: Clinical outcomes at 1 year stratiﬁed by tertiles of SYNTAX score II.
Outcomes at one year SxSIILow≤21.5 SxSIIMid 21.5–30.6 SxSIIHigh ≥30.6 p value N � 734
N � 245 N � 245 N � 244
All-cause mortality 2 (0.8) 3 (1.2) 23 (9.4) <0.001 28 (3.8)
Cardiovascular death 1 (0.4) 3 (1.2) 17 (7.0) <0.001 21 (2.8)
Noncardiovascular death 1 (0.4) 0 (0.0) 6 (2.4) 0.007 7 (0.9)
Cerebrovascular event 0 (0.0) 1 (0.4) 3 (1.2) 0.134 4 (0.5)
Myocardial infarction 1 (0.4) 9 (3.7) 10 (4.1) 0.011 20 (2.7)
Clinically driven revascularization 4 (1.6) 16 (6.5) 21 (8.6) 0.002 41 (5.6)
Target vessel revascularization 2 (1.7) 13(5.3) 13 (5.3) 0.011 28 (3.8)
Any revascularization 4 (1.6) 18(7.3) 21 (8.6) 0.002 43 (5.8)
Restenotic lesion revascularisation 3 (1.7%) 2 (1.2%) 9 (1.8%) 0.03 14 (1.9)
Any stent thrombosis 2 (1.1%) 0 (0%) 3 (1.9%) 0.59 5 (0.6)
Early thrombosis 1 (0.6%) 0 (0%) 2 (1.3%) 0.50 3 (0.4)
Late thrombosis 1 (0.6%) 0 (0%) 1 (0.6%) 0.77 2 (0.2)
MACE 5 (2.0) 20 (8.2) 35 (14.3) <0.001 60 (7.4)
MACCE 6 (2.4) 21 (8.6) 43 (17.6) <0.001 70(9.5)
MACE, major adverse cardiac events; MACCE, major adverse cardiac and cerebrovascular events.
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3.3. A Comparison between SxSII, SxS, and GRACE Score.
ROC curves showed an improved area under the curve
(AUC) when comparing SxSII with SxS regarding all-cause
mortality at 1 year (0.803 (0.773–0.831) versus 0.658
(0.622–0.692)) (Figure 2(a)). is improvement was statis-
tically signicant at an AUC dierence of 0.145 (95% CI
0.049–0.246, p  0.0045). Compared with the GRACE risk
score (calculated in 500 patients), SxSII showed a persis-
tently higher prognostic accuracy for all-cause mortality
(Figure 2(b)). Conversely, prognostic accuracy for MACE
during 1-year follow-up (AUC (0.657 (0.621–0.691) versus
0.684 (0.649–0.718), pDifference  0.475) was not dierent
between SxS and SxSII (Supplementary Figure 2).
Additionally, we sought to authenticate the benet in
risk assessment, that we have seen so far by SxSII over
SXS, through performing a category-free and category-
based net reclassication improvement (NRI) along with
integrated discrimination improvement (IDI) for the
outcome of all-cause mortality at 1 year. We found
a signicant categorical net reclassication improvement
of 0.344 (p  0.004) with Z score of 2.714 for all-cause
mortality, primarily driven by a signicant net gain of
0.321 (p  0.006) in patients who had the event and
a trend (p  0.39) in patients without the event (Table 5).
More importantly, both estimates of category-free net
reclassication improvement (NRI) and integrated dis-
crimination improvement (IDI) were signicant
(p< 0.001) at 0.380 95% CI (0.191–0.554) and 0.08 95% CI
(0.035–0.278), respectively. e red shaded area and its
extent show a substantial added value of the SxSII model
over SxS (Figure 3).
3.4. Results from Multivariable Analysis. For model
construction, variables which were found to correlate sig-
nicantly with the studied outcomes were plotted (Sup-
plementary Figures 3 and 4) as part of hazard assessment in
a univariable Cox regression analysis. e anatomical
SYNTAX score, age, LVEF, and GFR were predictive of
the primary outcome; however, they correlated signi-
cantly with SxSII while at the same time showing multi-
collinearity exceeding the acceptable threshold of VIF<3.
Hence, two separate models for SxSII and SxS were
constructed, showing the SxSII to be a signicant predictor
of all-cause mortality (adjusted HR 1.095 95% CI (1.05–
1.13), p< 0.001) along with the presence of left main dis-
ease, fasting glucose, and resuscitation status (Table 6). On
the other hand, the anatomical SYNTAX score got short of
signicance for the prediction of our primary outcome
(adjusted HR 1.013 95% CI (0.956–1.073), p  0.656). e
complete list of predictors in multivariable analysis for the
outcomes of MACE and MACCE is shown in Supple-
mentary Table 2.
Additional analysis regarding the impact of categorizing
patients within tertiles of SxSII showed that a classication
into SxSIIHigh independently predicted all-cause mortality
(HR 12.48, 95% CI (2.61−59.01], p  0.002), MACCE (HR
7.310, 95% CI (2.90−18.3), p< 0.001), and MACE (HR 6.64,
95% CI (2.42–18.18), p< 0.001) as compared to the ref-
erence category SxSIILow.
Further evaluation of the value of the SxSII over the
established GRACE risk score, which can be assessed
without information on coronary anatomy, was conducted
through an additional multivariable Cox regression model
to predict 1-year all-cause mortality. e results showed
that SxSII unlike GRACE score remained to be signicantly
predictive of mortality (adjusted HR 1.061 95% CI (1.01–
1.11), p  0.014) (Supplementary Table 3).
4. Discussion
To the best of our knowledge, this is the rst study to
evaluate and compare the novel SxSII score in patients with
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Figure 1: Kaplan–Meier survival curves at 1-year follow-up for freedom from all-cause mortality, MACCE, and MACE.
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ACS undergoing PCI with the currently available SxS and
GRACE risk scores. e following key ndings were
obtained:
(i) SxSII independently predicts all-cause mortality,
MACE, and MACCE during 1-year follow-up.
(ii) SxSII provides superior discrimination of risk for all-
cause mortality and MACCE than the conventional
SxS and GRACE score, respectively.
In the current era of interventional cardiology, the role of
the multidisciplinary HeartTeam in choosing the optimal
available means of revascularization is emphasized by current
ESC guidelines [2] advocating the use of the anatomical
SYNTAX score as a fundamental tool to assist in the decision
making for surgical versus percutaneous coronary re-
vascularization in stable coronary artery disease patients with
left main or multivessel disease [2]. However, risk assessment
and the prediction of long-term outcomes in patients pre-
senting with ACS undergoing PCI is still suboptimal with
a wide range of old and newly emerging risk scores [10].
e SxS has been extensively studied for a variety of
clinical outcomes in dierent patient populations including
all-comers [21, 22] as well as patients with NSTEMI [23, 24]
or STEMI [25, 26]. e recently developed SxSII has been
complemented with clinically signicant prognostic vari-
ables, known to be independent predictors of mortality at 4
years in patients with stable CAD enrolled in the SYNTAX
trial [9, 25, 27]. In that patient population, this was trans-
lated into better discrimination of risk for long-term
mortality for SxSII when compared to SxS [9]. e main
ndings from our study support the superiority of SxSII also
in patients with ACS undergoing PCI who are at particular
risk as it was found to be an independent predictor of all-
cause mortality during 1-year follow-up. In contrast, the
anatomical SYNTAX score was not an independent pre-
dictor for this endpoint, in line with previous studies
[22, 28, 29]. e discrepant ndings between studies eval-
uating the anatomical SYNTAX score to predict adverse
clinical outcome (particularly all-cause mortality) are likely
attributable to the heterogeneous patient population ana-
lyzed (inclusion or exclusion of patients with STEMI and/or
cardiogenic shock). Indeed, the latter patients tend to have
a worse outcome which is not predicted by anatomical
complexity alone. Furthermore, dierent cutos used in
statistical models to calculate SxS may explain the observed
dierences.
To further substantiate the signicant improvement in
discrimination or risk for all-cause mortality identied for
SxSII, we compared this score to the clinically based, ESC-
advocated risk stratication in patients with NSTEMI [2],
the GRACE risk score [13]. Despite the fact that patients
with cardiogenic shock with high GRACE risk scores were
included in our cohort, the SxSII showed greater discrim-
ination of risk for all-cause mortality during 1-year follow-
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Figure 2: ROC curves. (a) Receiver-operating characteristic (ROC) curves for SYNTAX score II and anatomical SYNTAX in predicting 1-
year all-cause mortality (entire population of 734 patients). SxSII (red line) signicantly improves prediction over both scores. AUC area
under the curve; CI condence intervals. (b) Receiver-operating characteristic (ROC) curves for SYNTAX score II, anatomical SYNTAX,
and GRACE risk score in predicting 1-year all-cause mortality (subanalysis of 500 patients).
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up. e GRACE risk score lacks some clinical variables
which are important predictors of mortality, such as LVEF,
as well as classiers of complex coronary anatomy [30–33],
which may explain the reduced prognostic accuracy to
predict all-cause mortality when compared with the SxSII.
In our study, SxSII also showed good prognostic ac-
curacy for the secondary endpoint of MACCE. Conversely,
SxSII provided no incremental risk stratication for MACE
compared with SxS. is could be explained by the fact that
MACE, which were primarily attributable to MI and
clinically indicated revascularization in a population with
complex coronary anatomy (i.e., a mean SxS of 17.56± 9.3,
44% MVD and 63.5% LAD involvement), could be well
predicted by pure anatomical complexity [34–36] as
assessed by SxS. Indeed, in our multivariable analysis,
multivessel disease was a predictor of MACE and MACCE
when assessed with both models of SxSII. However, it fell
short of signicance for all-cause mortality along with the
anatomical which is concordant with previously published
studies [6].
Importantly, SxSII enabled reclassication of risk for all-
cause mortality compared with SxS. is was highly sig-
nicant for 1-year follow-up with a persistent net gain of
approximately 33%. Upon exploring the dierences in
complexity of the coronary anatomy between tertiles of SxSII
and SxS, patients would still classify in the middle category
of the original anatomical SxS, although the anatomical
SYNTAX score in the SxSIIHigh group was higher as com-
pared to that in SxSIIMid and SxSIILow. erefore, the use of
SxSII for risk stratication in patients with ACS undergoing
PCI identies a distinctive group of patients who despite
having moderately complex coronary artery disease are still
at a signicantly higher risk of both cardiovascular and
noncardiovascular death during follow-up. ese are pa-
tients with multiple risk factors and comorbidities who may
benet from intensive secondary prevention, particularly
from some of the most recent lipid-lowering drugs [14, 37-
39] and risk factor modication with closer follow-up in-
tervals and may derive an advantage of full revascularization
when multivessel disease is present.
Surprisingly enough, diabetes was not a predictor of
clinical outcomes, which could be explained by the fact that
end-organ damage secondary to diabetes—as re©ected by
scores re©ecting coronary anatomy and calcication—rather
than metabolic parameters better re©ect risk in this patient
population [9, 13, 40]. Interestingly, abnormal fasting glu-
cose levels during hospitalization for the index event were
predictive of all-cause mortality irrespective of the diabetes
Table 5: Category-based NRI by SxSII.
Tertiles of SxSII Number of
patientsLow Mid High
Patients with an event
Tertiles of SxS
Low 1 1 3 517.90%
Mid 1 2 6 932.10%
High 0 0 14 1450%
All-cause mortality 2 3 23 287.10% 10.70% 21.10% 100.00%
Patients without an event
Tertiles of SxS
Low 134 67 45 24634.80%
Mid 79 97 59 23533.30%
High 30 78 117 22531.90%
All-cause mortality 243 242 221 70934.40% 34.30% 31.10% 100.00%
Number of patients with events moving 1 scale up by SxSII 10, number of
patients with events moving 1 scale down by SxSII 1, number of patients
without events moving 1 scale down by SxSII 187, and number of patients
without events moving 1 scale up by SxSII 171. Category-based
NRI 0.344, z 2.833, p  0.004.
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Figure 3: Category-free IDI and NRI. e red shaded area shows
a signicant integrated discrimination improvement (IDI), whereas
the dierence between the two vertical dots represents the im-
provement in net reclassication by SXSII over SxS.
Table 6: Multivariable predictors of all-cause mortality at one year.
HR (95% CI) p value
Variables in SxSII model All-causemortality
SxSII 1.095 (1.05–1.13) <0.001
LM disease 4.825 (1.40–16.59) 0.0125
Fasting glucose 1.081 (1.01–1.15) 0.0268
Resuscitation 11.48 (4.53–29.06) <0.001
Gender (male) 0.369 (0.126–1.08) 0.0685
H&L test: X2:3.156,df:8,p:0.9
Variables in SXS model All-causemortality
Age 1.106 (1.05–1.16) <0.0001
GFR 1.011 (0.99–1.02) 0.14
LVEF 0.937 (0.90–0.97) <0.001
LM disease 3.491 (0.93–12.9) 0.06
Resuscitation 19.7 (6.97–55.6) <0.0001
Fasting glucose 1.13 (1.05–1.23) 0.0015
SXS 1.013 (0.956–1.073) 0.656
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status of the patients. Indeed, in line with previous studies,
fasting glucose was also an independent variable capable of
predicting all-cause mortality in this population [41–44].
e pathophysiological mechanisms are well described
elsewhere [45–47], including but not limited to the eﬀects on
the collateral circulation, infarct size, reperfusion, sympa-
thetic activation with elevated catecholamine levels leading
to hepatic glucose release and platelet aggregation.
4.1. StudyLimitations. One limitation of our study is the fact
that due to the low number of patients undergoing CABG or
medical therapy in this ACS population, risk by SxSII in the
primary PCI group could not be compared to these diﬀerent
treatment modalities. Furthermore, since the SxSII was
developed using prognostic variables in a population where
STEMI patients were excluded, there may be additional
parameters that could further improve risk stratiﬁcation of
adverse clinical outcome.
5. Conclusion
In the present study, we demonstrate a clinically relevant
superiority of the novel SYNTAX score II when compared to
the anatomical SYNTAX and commonly used GRACE risk
score, in risk stratiﬁcation of patients with ACS undergoing
PCI. Pending validation in other cohorts, our data suggest
that the use of the SYNTAX score II opens a new door for
improvement in decision making and management of pa-
tients with ACS.
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